The stock of FibroGen Inc. (NASDAQ:FGEN) decreased by $0.0 on Tuesday to finish at $0.79, up 0.19 percent. The last five days have seen an average of 11,220,120 shares of common stock traded. 10 times new highs were reached in the current year, with a fall of -$15.2285. The average number of shares traded over the last 20 days was 6,067,555, while the average volume over the last 50 days totaled 4,391,288.
FGEN stock dropped -41.37% since last month. On 09/19/23, the company’s shares reached a one-month low of $0.7010. The stock touched a high of $25.69 on 02/03/23, after rallying from a low of $0.78 in 52 weeks. The price of FGEN stock has declined by -95.06% or -$15.2285 this year, reaching a new high 10 times. Still, the stock price is down -96.92% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
FGEN stock investors should be aware that FibroGen Inc. (FGEN) stock had its last reported insider trading activity 19 days ago on Sep 01. On Sep 01, Director Henderson Jeffrey William sold 2,000 shares at $1.03 each. This transaction resulted in the insider making $2,060. On Aug 04, Henderson Jeffrey William sold 2,000 shares at a price of US$1.91. After the transaction, the insider now owns 30,866 shares. Director Henderson Jeffrey William had earlier sold 2,000 shares on Jul 11 for $2.69 a share. The transaction was completed for $5,380.
Financial Health
For the three months ended June 29, FibroGen Inc.’s quick ratio was 1.90, while its current ratio was 2.10, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 85.90% percent. Based on annual data, it had gross profit of $120.45 million and revenue of $140.73 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. FGEN’s return on assets (ROA) during the last 12 months has been -56.70%. There was a 7008.90% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 881.20%.
Earnings Surprise
According to FibroGen Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $44.32 million, while revenues rose by 32.74% to $36.16 million. It was predicted that FibroGen Inc.’s quarterly earnings would be -$0.9, but it ended up being -$0.7, beating the consensus by -28.60%. EBITDA was -$86.46 million for the quarter. At the end of FibroGen Inc.’s most recent quarter ended June 29, its liabilities totaled 596.91 million, while its total debt was $173.6 million. Equity owned by shareholders amounts to $98.21 million.
Technical Picture
Here’s a quick look at FibroGen Inc.’s (FGEN) price momentum from a technical perspective. As of 19 September, the RSI 9-day stood at 25.87%, suggesting the stock is oversold, with a 117.18% historical volatility rate.
The stochastic %K and %D were 11.62% and 8.14% respectively, while the average true range (ATR) was 0.1144. Based on the 14-day stochastic reading of 22.13%, the RSI (14) reading is 24.14%. On the 9-day MACD Oscillator, the stock is at -0.1095, and the 14-day reading is at -0.1375.
Analyst Ratings
FibroGen Inc. (NASDAQ: FGEN) was downgraded by BofA Securities to a an Underperform rating in its latest research report. The stock was previously rated as a a Neutral. Analysts have assigned FibroGen Inc. (FGEN) an Underweight rating. FGEN is a stock that is recommended for selling by 1 brokerage firm, while 3 companies recommend holding. The stock is underweighted by 1 analyst. Among the analysts who rate the stock, 0 rates it overweight and 0 others recommend it as a buy.
What is FGEN’s price target for the next 12 months?
The current consensus forecast for the stock is between $2.00 and $2.50, with a median target price of $2.25. In analyzing these forecasts, the average price target given by analysts for FibroGen Inc. (FGEN) is $2.25.
